Avadel Pharmaceuticals plc’s (AVDL) lead drug candidate FT218 awaits the FDA decision on October 15, 2021.FT218 is an investigational, once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. Narcolepsy is a sleep disorder characterized by excessive sleepiness, sleep paralysis, hallucinations, and in some cases episodes of cataplexy (partial or total loss of muscle control, often triggered by a strong emotion such as laughter).Sodium Oxybate is marketed by Jazz Pharma as Xyrem in a twice nightly formulation for cataplexy and excessive daytime sleepiness in patients with narcolepsy. Xyrem’s annual net product sales in 2020 were $1.74 billion, up 6% over 2019. AVDL closed Wednesday’s trading at $9.91, up 0.51%.